Roche
OTC:RHHBYPharmaBasel, Switzerland · Est. 1896 · 100,000 employees
Global pioneer in pharmaceuticals and diagnostics.
124
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
167
Indications↗
Distinct diseases across all programs
2,617
Clinical Trials↗
All sponsored trials (all statuses)
68
Orange Book Patents
Across 9 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
124 drugs in development
Approved5
Phase 341
Phase 246
Phase 149
Preclinical27
By Therapeutic Area
top 6
Oncology
6135%
Neurology
2615%
Immunology
169%
Ophthalmology
127%
Rare Disease
127%
Hematology
95%
R&D Momentum
100/100
Pipeline Velocity
80/100
Trial Completion Rate
87/100
Pipeline Concentration
17/100
Pipeline Freshness
63/100
Strategic Signals
- ↗Active in Musculoskeletal but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Aug 28, 2026
Recruiting
A Phase IIb, Multicenter, Double-blind, Placebo-controlled Induction Study With an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients With Moderately to Severely Active Ulcerative Colitis
Aug 28, 2026
Active, not recruiting
An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study
Aug 27, 2026
Completed
A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients With Mild or Moderate Hemophilia A Without FVIII Inhibitors
Aug 27, 2026
Terminated
A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Aug 27, 2026
Active, not recruiting
A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers
Aug 27, 2026
Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
Aug 27, 2026
Active, not recruiting
A Phase III, Multicenter, Single Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
Aug 27, 2026
Active, not recruiting
An Open-Label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, A CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Aug 27, 2026
Terminated
A Multicenter, Prospective Epidemiologic Study of The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Aug 26, 2026
Active, not recruiting
A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
Aug 26, 2026
Recruiting
A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation
Aug 26, 2026
Recruiting
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Details
Company Info
Company Overview
$240.0B
Mkt Cap
$58.7B
Revenue
$8.4B
Cash
CEOThomas Schinecker
Founded1896
Employees100,000
HQBasel, Switzerland
ExchangeOTC:RHHBY
Websiteroche.com
LinkedInCompany Page
Therapeutic Focus
OncologyRare DiseaseImmunologyHematologyCardiovascularMusculoskeletalOtherOphthalmologyDermatologyNeurologyPsychiatryNephrologyRespiratoryInfectious DiseaseGastroenterologyMetabolic & Endocrine
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(5 drugs)
—
2
2
2
—
Cardiovascular(5 drugs)
Dermatology(2 drugs)
—
—
1
1
—
Dermatology(2 drugs)
Gastroenterology(4 drugs)
1
—
2
1
—
Gastroenterology(4 drugs)
Hematology(9 drugs)
3
1
2
4
—
Hematology(9 drugs)
Immunology(16 drugs)
1
6
7
4
—
Immunology(16 drugs)
Infectious Disease(2 drugs)
1
—
1
—
—
Infectious Disease(2 drugs)
Metabolic & Endocrine(5 drugs)
—
3
4
—
—
Metabolic & Endocrine(5 drugs)
Musculoskeletal(1 drug)
—
—
—
—
1
Musculoskeletal(1 drug)
Nephrology(6 drugs)
—
2
3
2
—
Nephrology(6 drugs)
Neurology(26 drugs)
—
7
13
7
1
Neurology(26 drugs)
Oncology(61 drugs)
16
30
20
18
1
Oncology(61 drugs)
Ophthalmology(12 drugs)
2
3
4
8
2
Ophthalmology(12 drugs)
Rare Disease(12 drugs)
3
1
4
3
1
Rare Disease(12 drugs)
Respiratory(4 drugs)
—
2
1
1
—
Respiratory(4 drugs)
Unknown / Other(10 drugs)
2
3
3
1
2
Unknown / Other(10 drugs)
Regulatory
Regulatory Timeline
20203 events
FDANov 23
Xofluza — XOFLUZA
Application NDA214410 (NDA)
FDAAug 14
ENSPRYNG — ENSPRYNG
Application BLA761149 (BLA)
FDAAug 7
Evrysdi — EVRYSDI
Application NDA213535 (NDA)
20211 event
FDAOct 22
Lucentis — SUSVIMO
Application BLA761197 (BLA)
20222 events
FDADec 22
LUNSUMIO — LUNSUMIO
Application BLA761263 (BLA)
FDAJan 28
Vabysmo — VABYSMO
Application BLA761235 (BLA)
20235 events
FDADec 6
Avastin — AVZIVI TNJN
Application BLA761198 (BLA)
FDAOct 20
Rozlytrek — ROZLYTREK
Application NDA218550 (NDA)
FDASep 29
Actemra — TOFIDENCE
Application BLA761354 (BLA)
FDAJun 15
COLUMVI — COLUMVI
Application BLA761309 (BLA)
FDAMar 22
Rezzayo — REZZAYO
Application NDA217417
20243 events
FDAOct 10
Fotivda — ITOVEBI
Application NDA219249 (NDA)
FDAJun 20
PIASKY — PIASKY
Application BLA761388 (BLA)
FDAMay 1
CellCept — MYHIBBIN
Application NDA216482 (NDA)
20254 events
FDADec 10
Rezzayo — REZZAYO
Application NDA217417
FDAMay 14
PIASKY — PIASKY
Application BLA761388
FDAFeb 11
Evrysdi — EVRYSDI
Application NDA219285 (NDA)
FDAJan 24
Actemra — AVTOZMA
Application BLA761420 (BLA)
20262 events
FDAJul 16
Rezzayo — REZZAYO
Application NDA217417
FDAJan 21
Actemra — AVTOZMA
Application BLA761498 (BLA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)